4:13 PM
 | 
Jul 03, 2013
 |  BC Extra  |  Company News

Roche's obinutuzumab gets Priority Review for CLL

FDA accepted and granted Priority Review to a BLA from Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit for obinutuzumab ( GA101) to...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >